Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in HFpEF (EMBARK-HFpEF)
NCT04766892Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mavacamten in heart failure with preserved ejection fraction (HFpEF), sponsored by Bristol Myers Squibb. Started Mar 2021; status: completed.
02
Drugs
mavacamten
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04766892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766892.